anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sixty-six permanent mature necrotic incisors associated with apical periodontitis in male children were selected. Teeth were randomly divided into three groups (n=22) according to intra canal medications used; group I: Ca OH2, group II: garlic extract and group III: mixture of Ca OH2 and garlic extract. After access preparation, four microbiological samples (S) were taken using sterile absorbent paper points as follows; (S1): were taken before canal instrumentation and irrigation. (S2): after cleaning and shaping, Then, the third samples (S3) and forth samples (S4) were taken after placement of the tested intracanal medications into the corresponding canals, for 7 and 14 days respectively. Total DNA was extracted from microbiological samples and relative quantitive real time PCR reactions were done to quantify the relative gene expression levels (FC) for Streptococcus and Enterococcus faecalis species. Data was statistically analyzed using Kruskal-Wallis and Freidman's tests, followed by Mann-Whitney and Wilcoxon singed rank tests at significance level p ≤ 0.05.
The detoxified pneumolysin derivative ΔA146Ply has been proven to have a direct anti-triple negative breast cancer effect by our group, but its work model remains unclear. In this study, we focused on its ability to inhibit triple-negative breast cancer metastasis. We found that ΔA146Ply suppressed the migration and invasion of triple-negative breast cancer cells by activating mannose receptor and toll-like receptor 4. Their activation triggers the activation of the mammalian target of rapamycin signalling, sequentially leading to autophagy, transforming growth factor-β1, and epithelial-mesenchymal transition inhibition. Furthermore, the combination of doxorubicin and ΔA146Ply significantly inhibited triple-negative breast cancer progression and prolonged survival in tumour-bearing mice. Taken together, our study provides an alternative microbiome-based mannose receptor-targeted therapy for triple-negative breast cancer and a novel theoretical and experimental basis for the downstream signalling pathway of the mannose receptor.
Patients will receive a 5-day, once-daily frequency-specific patterned rTMS treatment via a circular coil applied to the auditory cortex. Each session will last 40 minutes and will be stimulated at an intensity of 80% resting motor threshold (RMT).
Botulinum toxin has been shown to be useful for the treatment of pain when administered for cervical dystonia. Given efficacy for pain relief in regional dystonia, further expanded applications have included myofascial pain, muscle tension headaches, and other forms of headache syndromes. The application in headache practice has expanded to migraine as well as certain secondary headache syndromes. Although multiple case reports involving the use of botulinum toxin have shown promise in its utility for the treatment of primary pain syndromes, to date, controlled trials have failed to consistently and more definitively prove utility. Described herein is a method for selection of patients with headache syndromes more likely to respond to botulinum administration. The method involves identifying coincident diseases and signs within the patient's medical history, and selecting such patients for induction into clinical studies for pain or preferential primary treatment of pain using a botulinum based pharmaceutical.
PURPOSE:A fine pwoder of water-soluble diluent is uniformly dispersed in a solution of a substance activating lung surfaces in an organic solvent, then the dispersion is evaporated to dryness to give a dust preparation which can develop sufficient effect as a remedy for hyperpnea syndromes without reduction in its specific surface activity. CONSTITUTION:A substance activating lung surfaces is dissolved in an organic solvent, preferably chloroform, methylene chloride, THF or ether and 20-30, preferably 5-20pts.wt. per 1pt.wt. of the substance, of a water-soluble diluent fine powder, which is insoluble or hard soluble in the organic solvent are added to the resultant solution to effect uniform dispersion. The resultant dispersion is evaporated to dryness rapidly at a temperature at which the substance is not deactivated to give the objective dust preparation. As water-soluble diluents, are used essential aminoacids such as glycine or alanine, saccharides such as glucose or galactose or antibiotics such as cefazolin or gentamycin.
The invention relates to a preparation method of traditional Chinese medical lotion for remedying coldness and stagnation type ecthyma, which belongs to the technical field of a preparation method of traditional Chinese medicine. At present, the coldness and stagnation type ecthyma is treated generally with antibiotics and sulfonamides. When aztreonam is adopted, parageusia, rash, and gentle gastroenteric reaction sometimes occur, local pain can be caused by intramuscular injection, and phlebitis can be caused by intravenous injection. According to the technical scheme, 28 traditional Chinese medicines including fructrs litseae, fennel, leek, galangal, selinum, pepper, caraway, rhizoma kaempferiae, radix aconite, carmichaeli, radix pseudostellariae, white lablab beans, jujube, yam, black-bone chicken, cabbage, arillus longan, atractylodes macrocephala koidz, radix panacis quinquefolii, lotus seed, codonopsis, fructus alpiniae oxyphyllae, radix astragali preparata, polygonatum root, polished round-grained rice, dried ginger, long pepper and liquorice are soaked in water and decocted by slow fire, and the prepared lotion is the traditional Chinese medical lotion for remedying coldness and stagnation type ecthyma. The preparation method provided by the invention has the advantages that the traditional Chinese medical lotion has fewer toxic and side effects, the treatment course is short, and the recovery rate is high. Moreover, adverse reactions of western medicine can also be avoided.
Pregnancy Category B: Reproduction studies have been performed in rabbits, mice, and rats at oral or subcutaneous doses up to 32 times the maximum recommended human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to cyproheptadine. Cyproheptadine has been shown to be fetotoxic in rats when given by intraperitoneal injection in doses four times the maximum recommended human oral dose. Two studies in pregnant women, however, have not shown that cyproheptadine increases the risk of abnormalities when administered during the first, second and third trimesters of pregnancy. No teratogenic effects were observed in any of the newborns. Nevertheless, because the studies in humans cannot rule out the possibility of harm, cyproheptadine should be used during pregnancy only if clearly needed. 

  
Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from cyproheptadine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother (see CONTRAINDICATIONS). 

  
Pediatric Use: Safety and effectiveness in children below the age of two years have not been established. (See CONTRAINDICATIONS, Newborn or Premature infants, and WARNINGS, Children.)
The recommendations for Levoleucovorin injection rescue are based on a methotrexate dose of 12 grams/m2 administered by intravenous infusion over 4 hours (see methotrexate package insert for full prescribing information). Levoleucovorin injection rescue at a dose of 7.5 mg (approximately 5 mg/m2) every 6 hours for 10 doses starts 24 hours after the beginning of the methotrexate infusion. 

Serum creatinine and methotrexate levels should be determined at least once daily. Levoleucovorin injection administration, hydration, and urinary alkalinization (pH of 7.0 or greater) should be continued until the methotrexate level is below 5 x 10-8 M (0.05 micromolar). The Levoleucovorin injection dose should be adjusted or rescue extended based on the following guidelines.

Table 1 Guidelines for Levoleucovorin injection Dosage and Administration

Patients who experience delayed early methotrexate elimination are likely to develop reversible renal failure. In addition to appropriate levoleucovorin injection therapy, these patients require continuing hydration and urinary alkalinization, and close monitoring of fluid and electrolyte status, until the serum methotrexate level has fallen to below 0.05 micromolar and the renal failure has resolved. 

Some patients will have abnormalities in methotrexate elimination or renal function following methotrexate administration, which are significant but less severe than the abnormalities described in the table above. These abnormalities may or may not be associated with significant clinical toxicity. If significant clinical toxicity is observed, Levoleucovorin injection rescue should be extended for an additional 24 hours (total of 14 doses over 84 hours) in subsequent courses of therapy. The possibility that the patient is taking other medications which interact with methotrexate (e.g., medications which may interfere with methotrexate elimination or binding to serum albumin) should always be reconsidered when laboratory abnormalities or clinical toxicities are observed. 

Delayed methotrexate excretion may be caused by accumulation in a third space fluid collection (i.e., ascites, pleural effusion), renal insufficiency, or inadequate hydration. Under such circumstances, higher doses of levoleucovorin injection or prolonged administration may be indicated. 

Although levoleucovorin injection may ameliorate the hematologic toxicity associated with high-dose methotrexate, levoleucovorin injection has no effect on other established toxicities of methotrexate such as the nephrotoxicity resulting from drug and/or metabolite precipitation in the kidney.
This is a multi-centre prospective observational study to develop new quantitative echocardiography diagnostic criteria sensitive to identify the presence of chronic pulmonary hypertension early in postnatal course. The investigators hypothesize that echocardiographic markers of pulmonary vascular resistance (PVR) and right ventricular (RV) function will allow early identification of extremely low birth weight (ELBW) preterm neonates who subsequently develop chronic pulmonary hypertension in association with chronic neonatal lung disease. More specifically, based on previous work and preliminary data, the investigators hypothesize that tricuspid annular plane systolic excursion (TAPSE- a routinely used marker of right heart function) and pulmonary artery acceleration time (PAAT- a routinely used marker of resistance in the pulmonary blood vessels) either alone or in combination will be the most sensitive parameters for early identification reducing the time to diagnosis compared to contemporary clinical practice.

The aim of the study is to recruit a large cohort of extreme premature neonates at two weeks of age and sequentially perform two "early-diagnostic assessments". First assessment will be performed between 14-21 days of life and the second at a corrected gestational age (CGA) of 32 weeks. Assessment will include a focused ultrasound of the heart to measure pre-defined markers which are under investigation. The investigators will test the diagnostic utility of these markers separately for each time point. All babies will also have a standard diagnostic assessment for evaluation of cPHT at 36 weeks CGA, as per routine practice. The study team will record this data for participants, along with their relevant medical details and clinical outcomes, including neurodevelopment assessments performed at 18 months of age as a routine clinical follow-up. At the end of this study, the investigators will divide the cohort into those who developed cPHT and those who did not as per currently used standard criteria and will compare the results of new parameters obtained at earlier time points. The sensitivity of each marker to pick-up early cPHT will be calculated and its correlation with health outcomes will be established.
Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection contains bupivacaine hydrochloride, an amide local anesthetic, as the active pharmaceutical ingredient. The route of administration for Bupivacaine Hydrochloride Injection (without epinephrine) is by injection, for infiltration, perineural, caudal, epidural, or retrobulbar use. The route of administration for Bupivacaine Hydrochloride and Epinephrine Injection is by injection, for infiltration, perineural, caudal, or epidural use. Multiple-dose vials contain methylparaben [see WARNINGS AND PRECAUTIONS (5.4)].

Bupivacaine hydrochloride is 2-piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, monohydrochloride, monohydrate. It is a white crystalline powder that is freely soluble in 95 percent ethanol, soluble in water, and slightly soluble in chloroform or acetone. It has the following structural formula:

Bupivacaine hydrochloride with 1:200,000 epinephrine, contains bupivacaine hydrochloride and epinephrine (an alpha and beta-adrenergic agonist) as active pharmaceutical ingredients. This product is for injection via local infiltration, peripheral nerve block, and caudal and lumbar epidural blocks. Multiple-dose vials contain methylparaben and they should not be used for caudal and lumbar epidural blocks.

Epinephrine is (-)-3,4-Dihydroxy-α-[(methylamino)methyl] benzyl alcohol. Epinephrine is a vasoconstrictor. It has the following structural formula:
Subjects presenting to ED with diagnosis of DKA will receive study medication set to begin within 2 hours after initiation of the IV insulin infusion. The dose will come from IV pharmacy and dispensed in a 1 mL insulin syringe. If the patient was not taking basal insulin prior to admission, the patient will receive 0.2 units/kg insulin glargine. If the patient was taking basal insulin prior to admission, the patient will receive their home insulin glargine dose.
Oral lesions can be the first presentation of hematological malignancy. Dentists occasionally are the first healthcare provider that detect oral signs related to a systemic condition and thus contribute to the early diagnosis of the disease 1. Oral health can impact the progression and the outcome of haematological malignancy patients', many patients may suffer from oral infections that might affect hospital stay, treatment cost and patient prognosis 2. The oral manifestations of patients with hematological malignancy can occur due to the disease itself or as a consequence of treatment 3.

Anemia (paleness of mucosa), coagulation disorder, oral petechiae or ecchymosis, spontaneous gingival bleeding and oral infection (Ulcers and overgrowth) may be an oral manifestation of a hematologic malignancy either at diagnosis or during follow up as well as in relapse 4. The treatment of hematologic malignancy includes chemotherapy, radiotherapy, and hematopoietic stem cell transplantation (HSCT). Malignant cells are the target of antineoplastic drugs, but the oral epithelium and other cells with high mitotic rates are usually affected by the treatment. Chemotherapy and the conditioning regimen for HSCT have many adverse effects on the oral tissues depending on the type and dosage of medications 4. Oral mucositis, a common side effect of chemotherapy, causes severe pain, which is only relieved by opioids. Mucositis may appear as a generalized erythema and evolve into painful pseudomembranous ulcers. Neutropenia and thrombocytopenia are also common adverse effects of treatment, leaving patients more susceptible to oral bleeding, infections, and ulcerations. Oral mucosa pigmentation can also occur as an adverse effect of treatment 5. Considering these factors and lack of existing information, a study was designed to investigate the prevalence of oral complications problems occurring in a population of hematological malignancy patients in Assiut University Hospital.
Subjects with clear cell renal cell carcinoma (ccRCC) expressing EGFR who recieved 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
The study is given to KSBU Faculty of Dentistry, Department of Oral, Dental and Maxillofacial Surgery; It will be applied to patients who are referred from Oral, Dental and Maxillofacial Radiology and who want to participate in the study. In our study, the Situational-Trait Anxiety Inventory will be used to assess anxiety. Patients who are referred to our clinic from Oral, Dental and Maxillofacial Radiology and who have impacted wisdom teeth will be evaluated in terms of extraction indication. Patients with indications for extraction will be asked to rate the sentences in the State and Trait Anxiety Inventory when making an appointment. Patients will be informed about impacted tooth extraction as it is routinely practiced. Within the scope of this study, no information about the extraction will be given in the Oral, Dental and Maxillofacial Radiology clinic, standard information will be given to the patients in our clinic and the surgery appointment will be given one week later. On the day of tooth extraction, patients will be asked whether they watched a video about impacted tooth extraction from any social media platform. The patients who watch the video will be assigned to the study group, and the patients who do not watch the video will be assigned to the control group, so the study will be conducted over two groups. If the patient has watched the video; He will be asked whether he watches an animation video or a video with real surgery footage, and the reason for watching the video. Then, before starting the operation, they will be asked to score the sentences in the Situational and Trait Anxiety Inventory. By comparing the Situational Anxiety Inventory made at the time of the surgery appointment with the Situational Anxiety Inventory scores made just before the surgery, it will be evaluated whether the patients who watch videos have more anxiety. At the same time, it will be evaluated whether the patients who have a high Trait Anxiety Inventory score when making an appointment and who generally have high anxiety watch more videos. This study is planned to be performed on a total of 60 patients, 30 of whom watch videos and 30 who do not.
BACKGROUND: Cancer and coronary artery disease (CAD) is reported to often co-exist in same individuals, however, whether cancer is directly associated with anatomical severity of CAD is rarely studied. The present study aimed to observe the relationship between newly diagnosed cancer and anatomical severity of CAD, moreover, to investigate effect of inflammation on the relationship of cancer with CAD.
METHODS: 374 patients with newly diagnosed cancer who underwent coronary angiography (CAG) were enrolled. Through 1:3 propensity score matching (PSM) to cancer patients based on the age and gender among 51,106 non-cancer patients who underwent CAG, 1122 non-cancer patients were selected as control patients. Anatomical severity of CAD was assessed using SYNTAX score (SXscore) based on coronary angiographic image. SXscore ≤ 22 (highest quartile) was defined as SX-low, and SXscore > 22 as SX-high. The ratio of neutrophil to lymphocyte count (NLR) was used to describe inflammation level. Association between cancer and the anatomical severity of CAD was investigated using logistic regression.
RESULTS: Univariate logistic regression analysis showed a correlation between cancer and anatomical severity of CAD (OR: 1.419, 95% CI: 1.083-1.859; P = 0.011). Cancer was associated with increased risk of SX-high after adjusted for common risk factors of CAD (OR: 1.598, 95% CI: 1.172-2.179, P = 0.003). Significant association between cancer and SX-high was revealed among patients with high inflammation (OR: 1.656, 95% CI: 1.099-2.497, P = 0.016), but not among patients with low inflammation (OR: 1.530, 95% CI: 0.973-2.498, P = 0.089).
CONCLUSIONS: Cancer was associated with severity of CAD, however, the association between the two diseases was significant among patients with high inflammation rather than among patients with low inflammation.
PROBLEM TO BE SOLVED: To obtain a non-rinsed composition containing a direct dye, etc., and cationic group-modified guar gum as a thickening agent, useful for dyeing keratin fibers, esp. the human hair, affording the fibers with glints and soft feel of touch, and favorable in color tone. SOLUTION: This composition comprises a direct dye and/or pigment and/or oxidative dye precursor and, as thickening agent, guar gum modified with pref. 5-20 wt.% of cationic group and/or nonionic guar gum, being intended for the direct or oxidative dyeing of human keratin fibers such as the hair. The nonionic guar gum is pref. one modified with 1-6C hydroxyalkyl group which is pref. hydroxymethyl, hydroxyethyl, hydroxypropyl or hydroxybutyl group.
Demographic characteristics of heart transplant recipients and organ donors were prospectively collected in a local database. All HTx successively performed in the Hospital Marie Lannelongue from 1990 to 2016 were included. From 1990 to 1997, both EMB and cardiac echo were routinely performed at each medical follow-up date. After 1997, only cardiac echo was used to detect early acute allograft rejection. The investigators collected the results of all EMB and synchronous cardiac echo in patients transplanted between 1990 and 1997 (group A, validation cohort), and clinical events and long-term survival in patients transplanted from 1998 to 2016 (group B, standardization cohort). For our purpose, the investigators graded the histological patterns of acute cardiac rejection according to the 1990 international classification. Cardiac echo assessment included the isovolumic relaxation time, E-wave velocity and E/A ratio. Impaired left ventricular relaxation was consistent with acute cardiac rejection.

The investigators therefore analyzed the rate of positive and negative EMB during the first post-transplant year and compared these results to the synchronous cardiac echo report in group A. Sensibility and specificity of cardiac echo to detect acute cardiac rejection were calculated. The rate of acute cardiac rejection during the first year was collected in group B and compared to group A. Finally, long-term survival was analyzed according to the Kaplan-Meier approach and compared between group A and B (log-rank test). The investigators hypothesize that the participant will not observe any differences between groups considering the rate of acute cardiac rejection during the first year. In addition, the investigators do not expect to find any significant difference in long-term survival between the two cohorts. These findings may have a major impact on HTx follow-up since systematic EMB could be replaced by a standardized cardiac echo protocol focusing on left ventricular wall relaxation. EMB should therefore only be indicated in case of acute allograft dysfunction without evidence of rejection on conventional cardiac echo.
The present invention belongs to the field of traditional Chinese medicine and pharmacy, which relates to the use of traditional Chinese medicine pulse-activating injection in preparing synergetic medicines for treating tumors. According to the characteristics of clinical chemotherapy, the present invention combines the use of pulse-activating injection and chemotherapeutic medicines in treating tumors. Malignant cell tests show that the pulse-activating injection has obvious synergistic effect on the chemotherapeutic medicines, particularly 5-Fu, MTX, DDP, etc. in cancer cells. The new use of the present invention expands the adaptation of the pulse-activating injection. The present invention can be used for synergetic medicines for the clinical treatment of malignant tumors, particularly colon cancers, liver cancers, mammary cancer and pancreatic cancers.